Prader-Willi Syndrome
Conditions
Brief summary
This is a Phase 3 open-label extension (OLE) study in patients diagnosed with Prader-Willi Syndrome (PWS) who completed the Maintenance Period of the randomized, placebo-controlled Phase 2/3 study SCOUT-015. The primary objective of this study is to assess the long-term safety and tolerability of RAD011.
Interventions
DRUGRAD011
Cannabidiol Oral Solution (containing synthetic cannabidiol)
Sponsors
Radius Pharmaceuticals, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
8 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Presence of a parent/legal guardian that is able to consent for their participation. Parent/caregiver/legal guardian can complete the required assessments throughout the study. Patient Consent/Assent will be obtained if the patient is 8 years of age or older and has the mental capacity to understand and sign a written consent/assent form and/or give verbal assent; * Patient completed treatment on the SCOUT-015 study through Visit 14 (Week 34); * If female, is either not of childbearing potential (defined as premenarchal or surgically sterile \[bilateral tubal ligation, bilateral oophorectomy, or hysterectomy\]) or practicing one of the following medically acceptable methods of birth control up to 4 weeks after the last dose of RAD011 or placebo:
Exclusion criteria
* Significant acute condition (active infection, uncontrolled diabetes, any other uncontrolled chronic condition) including but not limited to clinically significant laboratory abnormality, or medical or psychosocial condition that may preclude the patient from participating in the study, at the Investigator's discretion; * Positive urine test for drugs of abuse, including tetrahydrocannabinol (THC), or known history of drug, alcohol, or substance abuse; * Significant risk of committing suicide based on history, psychiatric examination, or based on the Investigator's judgment; * Significant non-compliance issues (IP misuse or abuse, study visit participation, etc.) during the patient's SCOUT-015 participation based on the Investigator's judgement. * Pregnant (determined by a positive urine pregnancy test) or lactating female; * Concurrent participation in any other interventional study involving an investigational product, gene therapy, or device.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess the safety of RAD011 by evaluating the incidence and severity of adverse events reported | Baseline through Week 52 | Safety analyses will be conducted in all subjects who receive at least one dose of RAD011 |
Outcome results
None listed